Recce Pharmaceuticals Ltd (AU:RCE) — Market Cap & Net Worth
Market Cap & Net Worth: Recce Pharmaceuticals Ltd (RCE)
Recce Pharmaceuticals Ltd (AU:RCE) has a market capitalization of $70.31 Million (AU$99.38 Million) as of September 24, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20684 globally and #697 in its home market, demonstrating a -7.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Recce Pharmaceuticals Ltd's stock price AU$0.33 by its total outstanding shares 305770071 (305.77 Million). Also see total assets of Recce Pharmaceuticals Ltd for a full breakdown of the balance sheet.
Recce Pharmaceuticals Ltd Market Cap History: 2016 to 2026
Recce Pharmaceuticals Ltd's market capitalization history from 2016 to 2026. Data shows growth from $35.70 Million to $70.31 Million (0.75% CAGR). Also see RCE operating cash flow for how efficiently the company converts equity into cash flow.
Recce Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Recce Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check RCE live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
18.73x
Recce Pharmaceuticals Ltd's market cap is 18.73 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $36.78 Million | $139.29K | -$3.03 Million | 264.04x | N/A |
| 2018 | $37.86 Million | $1.29 Million | -$1.67 Million | 29.38x | N/A |
| 2019 | $77.89 Million | $679.62K | -$2.79 Million | 114.60x | N/A |
| 2020 | $228.25 Million | $1.12 Million | -$4.32 Million | 203.48x | N/A |
| 2021 | $222.84 Million | $1.64 Million | -$13.51 Million | 136.10x | N/A |
| 2022 | $142.79 Million | $3.08 Million | -$10.99 Million | 46.29x | N/A |
| 2023 | $115.75 Million | $4.37 Million | -$13.08 Million | 26.52x | N/A |
| 2024 | $104.93 Million | $5.03 Million | -$17.66 Million | 20.87x | N/A |
| 2025 | $140.63 Million | $7.51 Million | -$21.43 Million | 18.73x | N/A |
Competitor Companies of RCE by Market Capitalization
Companies near Recce Pharmaceuticals Ltd in the global market cap rankings as of September 24, 2026. Review Recce Pharmaceuticals Ltd (RCE) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Recce Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Recce Pharmaceuticals Ltd Historical Marketcap From 2016 to 2026
Between 2016 and today, Recce Pharmaceuticals Ltd's market cap moved from $35.70 Million to $ 70.31 Million, with a yearly change of 0.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$70.31 Million | -50.00% |
| 2025 | AU$140.63 Million | +34.02% |
| 2024 | AU$104.93 Million | -9.35% |
| 2023 | AU$115.75 Million | -18.94% |
| 2022 | AU$142.79 Million | -35.92% |
| 2021 | AU$222.84 Million | -2.37% |
| 2020 | AU$228.25 Million | +193.06% |
| 2019 | AU$77.89 Million | +105.71% |
| 2018 | AU$37.86 Million | +2.94% |
| 2017 | AU$36.78 Million | +3.03% |
| 2016 | AU$35.70 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Recce Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $70.31 Million USD |
| MoneyControl | $70.31 Million USD |
| MarketWatch | $70.31 Million USD |
| marketcap.company | $70.31 Million USD |
| Reuters | $70.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti"infectives in Australia, the United Kingdom, and the United States. The company's lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary… Read more